XSTEM OA
Alternative Names: XSTEM-OALatest Information Update: 09 Jun 2022
At a glance
- Originator Xintela
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Osteoarthritis
Most Recent Events
- 31 May 2022 Phase-I/II clinical trials in Osteoarthritis in Australia (Intra-articular) (NCT05344157)
- 30 Apr 2022 Xintela plans a phase I/II trial in Osteoarthritis of knee in Australia, in April 2022 (Intra-articular, Injection) (NCT05344157)
- 25 Apr 2022 Preclinical trials in Osteoarthritis in Sweden (Intra-articular), prior to April 2022